Hennessy Advisors Inc. Cuts Stock Holdings in DaVita Inc. (NYSE:DVA)

Hennessy Advisors Inc. trimmed its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 10.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 65,800 shares of the company's stock after selling 7,500 shares during the period. Hennessy Advisors Inc. owned approximately 0.08% of DaVita worth $10,065,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. United Capital Financial Advisors LLC grew its position in DaVita by 2.6% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after buying an additional 62 shares during the period. Freedom Investment Management Inc. increased its holdings in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after purchasing an additional 62 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of DaVita by 2.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock worth $531,000 after purchasing an additional 69 shares during the last quarter. UMB Bank n.a. raised its stake in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Finally, Coppell Advisory Solutions LLC raised its stake in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA stock traded down $1.42 during trading on Friday, reaching $135.93. The company had a trading volume of 826,047 shares, compared to its average volume of 822,790. The firm has a 50-day simple moving average of $141.36 and a 200-day simple moving average of $151.08. The company has a market cap of $10.26 billion, a price-to-earnings ratio of 12.66, a price-to-earnings-growth ratio of 1.07 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a twelve month low of $131.76 and a twelve month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same period last year, the firm posted $2.26 EPS. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Truist Financial decreased their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Barclays increased their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, DaVita currently has a consensus rating of "Hold" and an average price target of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.